selected publications
- Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity. PloS one. 2025 Academic Article GET IT
- Repurposing riluzole as an anti-osteosarcoma agent. Frontiers in oncology. 2025 Academic Article GET IT
-
Delivery of mGluR5 siRNAs by Iron Oxide Nanocages by Alternating Magnetic Fields for Blocking Proliferation of Metastatic Osteosarcoma Cells.
International journal of molecular sciences.
2022
Academic Article
GET IT
Times cited: 4 -
Riluzole: A neuroprotective drug with potential as a novel anti‑cancer agent (Review).
International journal of oncology.
2021
Review
GET IT
Times cited: 47 -
Riluzole-induced apoptosis in osteosarcoma is mediated through Yes-associated protein upon phosphorylation by c-Abl Kinase.
Scientific reports.
2021
Academic Article
GET IT
Times cited: 7 -
Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice.
Oncology reports.
2019
Academic Article
GET IT
Times cited: 19 -
Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.
PloS one.
2017
Academic Article
GET IT
Times cited: 29 - The Effect of Cage Shape on Nanoparticle-Based Drug Carriers: Anticancer Drug Release and Efficacy via Receptor Blockade Using Dextran-Coated Iron Oxide Nanocages. Nano letters. 2016 Academic Article GET IT
-
Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.
PloS one.
2013
Academic Article
GET IT
Times cited: 38 -
Exposure of neurons to excitotoxic levels of glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss of GLUR2 editing.
Neuroscience.
2011
Academic Article
GET IT
Times cited: 37 -
Reactome: a database of reactions, pathways and biological processes.
Nucleic acids research.
2010
Academic Article
GET IT
Times cited: 1347